Tevogen Inc. TVGN
are a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes ("CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers,
and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability
and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $11.1M | $31.0M | $4.4M | — | — | — |
| SG&A | $15.0M | $22.5M | $4.4M | $953.1K | — | — |
| Total operating expenses | $26.1M | $53.6M | $8.8M | $953.1K | — | — |
| Operating income | -$26.1M | -$53.6M | -$8.8M | — | — | — |
| Interest expense | $195.6K | $184.0K | $1.2M | — | — | — |
| Pre-tax income | -$26.3M | -$13.7M | — | — | — | — |
| Income tax | $4.8K | $1.8K | — | — | — | — |
| Net income | -$26.3M | -$13.7M | -$60.5M | $4.4M | — | — |
| EPS, basic | -8.08 | -3.50 | -2.44 | — | — | — |
| EPS, diluted | -8.08 | -3.50 | -2.44 | — | — | — |
| Shares, diluted (wtd. avg.) | 3.3M | 2.9M | 24.8M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $1.1M | $5.5M | $344.6K | $0 |
| Total current assets | $1.5M | $2.4M | $1.7M | $274.4K | $791.2K | — |
| Property, plant and equipment | $170.3K | $296.4K | $458.7K | — | — | — |
| Total assets | $4.4M | $3.5M | $5.5M | $357.1M | $352.9M | — |
| Accounts payable | $3.3M | $5.2M | $3.4M | $210.5K | $39.4K | — |
| Short-term debt | — | — | — | $0 | — | — |
| Total current liabilities | $7.1M | $9.0M | $85.5M | $350.5K | $59.4K | — |
| Total liabilities | $12.6M | $10.1M | $99.9M | $15.1M | $15.2M | — |
| Retained earnings | -$139.7M | -$113.4M | -$99.7M | -$14.8M | -$14.2M | — |
| Total equity | -$8.2M | -$6.7M | -$94.4M | -$34.0M | -$14.2M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.3M | -$12.0M | -$8.2M | -$215.4K | — | — |
| Depreciation and amortisation | $190.6K | $162.2K | $163.3K | — | — | — |
| Stock-based compensation | $16.2M | $40.8M | — | — | — | — |
| Capital expenditure | $64.4K | — | $133.0K | — | — | — |
| Investing cash flow | -$64.4K | — | -$133.0K | — | — | — |
| Financing cash flow | $11.7M | $12.2M | $3.9M | — | — | — |
| Buybacks | — | — | $343.0M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020704.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | — | $4.4M | -$60.5M | -$13.7M | -$26.3M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Charter or fiscal year changed Item 5.03
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |